Regulatory Updates - The National Medical Products Administration (NMPA) has released the "Guidelines for Pharmaceutical Research on Chemical Drugs for Rare Diseases (Trial)" to enhance support for rare disease drug development and improve technical guidance principles [1] - Hengrui Medicine's innovative drug SHR-1918 injection has been accepted for priority review by the NMPA, aimed at treating patients with homozygous familial hypercholesterolemia [1] - CanSino Biologics has expanded the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, which is expected to positively impact the company's performance [2] - Tongrentang Pharmaceutical has received product registration approval from Health Canada for several products, including children's cough syrup, although further administrative approvals are required for sales [3] - Shanghai Pharmaceuticals has obtained a drug registration certificate in Singapore for rivaroxaban tablets, which are used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients [4] - Baotai has received acceptance for the marketing authorization application of its drug BAT4406F, intended for treating adult patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder [5] Industry Developments - Zhejiang Medicine plans to invest 250 million yuan in a silver economy fund in collaboration with a private equity fund, focusing on the healthcare sector [6] - Zhijiang Biology has completed a strategic increase in its stake in Sanyou Biopharmaceuticals, enhancing its position in the precision medicine sector [7] - Xianweida Biopharmaceutical has entered a commercialization agreement with Pfizer China for its GLP-1 receptor agonist, which could yield up to $495 million in payments [8] Financial Performance - Sangfor Technologies reported a projected net profit increase of 317.09% for 2025, driven by a significant collaboration with Pfizer that resulted in a revenue recognition of approximately 2.89 billion yuan [9] Capital Market Activities - Duorui Pharmaceuticals announced a stock suspension following the expiration of a tender offer period, pending confirmation of the offer results [10] - Jiutian Pharmaceutical completed a share buyback of 1.24% of its total shares, with a total transaction amount of 100 million yuan [11] - Shenlian Biopharmaceutical plans to acquire controlling interest in Shiziyuan Biotechnology for 237 million yuan, aiming to expand into innovative drug business [12]

Core Viewpoint - Shanghai Pharmaceuticals has received a drug registration certificate from the Health Sciences Authority of Singapore for its rivaroxaban tablets, allowing the product to be marketed in Singapore [1][4]. Group 1: Drug Basic Information - Drug Name: Rivaroxaban Tablets - Dosage Forms: Tablets - Specifications: 10mg, 15mg, 20mg - Registration Classification: Chemical Generic Drug - Manufacturer: Changzhou Pharmaceutical Factory Co., Ltd. - Registration Numbers: 10mg: SIN17463P, 15mg: SIN17462P, 20mg: SIN17461P [2]. Group 2: Drug Indications - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; for the treatment and prevention of deep vein thrombosis (DVT); for the treatment of pulmonary embolism (PE); and for the prevention of venous thromboembolism (VTE) in acutely ill patients [2]. Group 3: Market Competition - As of the announcement date, there are six other approved manufacturers in Singapore for rivaroxaban tablets, with BAYER being the main seller. The total sales amount for the three specifications (10mg, 15mg, 20mg) in the Singapore market is projected to be $8 million in 2024 [3]. Group 4: Impact on the Company - The approval of rivaroxaban tablets for sale in Singapore is expected to positively impact the company's efforts to expand into overseas markets and accumulate valuable experience [4].

Group 1 - Dongyangguang is planning to acquire control of Yichang Dongshu No. 1 Investment Co., Ltd. through a share issuance, leading to a stock suspension starting February 24, 2026, for up to 10 trading days [1] - Tongde Chemical has received an execution notice and ruling, resulting in the freezing and deduction of bank deposits amounting to RMB 53.93 million [2] - Palm Holdings is facing a lawsuit for a construction contract dispute with a claim amount of RMB 113 million, which represents 6.83% of the company's latest audited net assets [3] Group 2 - Duorui Pharmaceutical's tender offer period has expired, leading to a stock suspension starting February 25, 2026, after a tender offer for 19.44 million shares at RMB 32.07 per share [4] - Huazhi Media reported that the film "Silent Awakening" has grossed approximately RMB 901 million, exceeding 50% of the company's latest audited annual revenue [5] - Light Media announced that the film "Racing Life 3" has grossed about RMB 2.926 billion, also exceeding 50% of the company's latest audited annual revenue [6][7] Group 3 - Tongwei Co. is planning to acquire 100% of Lihua Qingneng Co., Ltd. through a combination of share issuance and cash payment, with a stock suspension starting February 25, 2026, for up to 10 trading days [8] - Meibang Co. confirmed that its operations are normal and there are no undisclosed significant information despite a stock price fluctuation exceeding 20% [9] - China Nuclear Construction's shareholder, China Cinda, has reduced its holdings by 8.0354 million shares, accounting for 0.2666% of the total share capital [10] Group 4 - Changxin Bochuang intends to acquire 93.81% of Shanghai Honghui Optical Communication Technology Co., Ltd. for a tentative price of RMB 375 million, aiming to enhance its capabilities in the optical communication sector [11] - Beingmei has had its patent contract dispute case accepted, with claims amounting to RMB 56.85 million, while also facing a counterclaim of RMB 77.25 million [12] Group 5 - Several companies have reported their 2025 net profit forecasts, with notable increases such as SanSheng Guojian at RMB 2.939 billion, a 317.09% increase year-on-year, while Wens Foodstuffs reported a decline of 43.59% to RMB 5.235 billion [13]

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for rivaroxaban tablets, allowing the product to be marketed [1] Group 1: Product Approval - Rivaroxaban tablets are approved for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating and preventing deep vein thrombosis, treating pulmonary embolism, and preventing venous thromboembolism in acutely ill patients [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing of rivaroxaban tablets produced by its subsidiary, Changzhou Pharmaceutical Factory [1] Group 1: Product Information - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat and prevent deep vein thrombosis (DVT), treat pulmonary embolism (PE), and prevent venous thromboembolism (VTE) in acutely ill patients [1] - The drug was originally co-developed by BAYER and JANSSEN and was first launched in the United States in 2011 [1] Group 2: Regulatory Approvals - The rivaroxaban tablets received approval from the U.S. Food and Drug Administration (FDA) in May 2025 and obtained a drug registration certificate in Malaysia in October 2025 [1] Group 3: Investment and R&D - As of the date of the announcement, the company has invested approximately RMB 3.2482 million in research and development for the drug's market entry in Southeast Asia, including Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority of Singapore for the marketing of its rivaroxaban tablets, marking a significant step in expanding its overseas market presence [1][2]. Group 1: Product Approval and Market Impact - The rivaroxaban tablets are indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. - The approval in Singapore is part of a broader strategy to enter Southeast Asian markets, with additional investments of approximately RMB 3.2482 million allocated for research and development related to this product [1]. - The presence of other approved manufacturers in Singapore, including Bayer, Teva, and Intega, indicates a competitive landscape, with Bayer being the primary seller [1]. Group 2: Market Data and Future Prospects - The total sales value of rivaroxaban tablets in Singapore for the year 2024 is projected to be USD 8 million across three specifications (10mg, 15mg, 20mg) [1]. - The approval of rivaroxaban tablets in Singapore is expected to have a positive impact on the company's efforts to expand its overseas market and gain valuable experience [2].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for the approval of rivaroxaban tablets for market launch [1] Group 1: Product Approval - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment and prevention of deep vein thrombosis (DVT) [1] - Additionally, it is used for the treatment of pulmonary embolism (PE) and for the prevention of venous thromboembolism (VTE) in acutely ill patients [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a drug registration certificate from the Singapore Food and Drug Administration for the drug rivaroxaban, which has been approved for market launch [1] Group 1: Product Approval - The drug rivaroxaban is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - It is also indicated for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in acutely ill patients [1] Group 2: Investment and R&D - As of the announcement date, the company has invested approximately RMB 3.2482 million in research and development for this drug's market launch in Southeast Asia, specifically in Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - The company announced that its subsidiaries and a holding subsidiary participated in a national procurement program and have proposed to be selected for six pharmaceutical products, with a procurement period extending until December 31, 2028 [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries, including Shaanxi Buchang High-tech Pharmaceutical Co., Ltd. and Shandong Danhong Pharmaceutical Co., Ltd., along with its holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd., are involved in the national organized procurement program [1] - The selected products include Amlodipine Besylate Tablets, Rivaroxaban Tablets, Metoprolol Tartrate Tablets, Lacosamide Tablets, Pregabalin Capsules, and Torasemide Injection [1] Group 2: Procurement Details - The procurement cycle for the selected drugs will commence from the actual execution date of the selection results and will last until December 31, 2028 [1]